Stocktoria
Profound Medical Corp. PROF
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2014-09-24
Profound Medical Corp. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M |
| Gross profit | $11.4M | $7.0M | $4.3M |
| R&D expense | $20.6M | $17.0M | $14.4M |
| SG&A expense | $32.1M | $23.1M | $18.5M |
| Operating income | -$41.3M | -$33.1M | -$28.7M |
| Income tax | $252,000 | -$2,000 | -$128,000 |
| Net income | -$42.6M | -$27.8M | -$28.3M |
| EPS (diluted) | $1.41 | $1.12 | $1.34 |
| Operating cash flow | -$38.2M | -$23.5M | -$22.6M |
| Free cash flow | -$38.4M | — | — |
| Cash & equivalents | $59.7M | $54.9M | $26.2M |
| Inventory | $8.2M | $5.8M | $7.0M |
| Total assets | $77.5M | $70.2M | $44.0M |
| Total liabilities | $11.0M | $9.8M | $12.7M |
| Shareholders' equity | $66.4M | $60.4M | $31.2M |
Growth · year-over-year · Revenue CAGR 49.5%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +50.7% | +48.4% | — |
| EPS growth | +25.9% | -16.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.